Biochemical mechanism of acetylsalicylic acid (Aspirin) selective toxicity toward melanoma cell lines

Melanoma Research

Volumn 18, Issue 6, 2008, Pages 386-399

  Vad, Nikhil M ^a   Yount, Garret ^c   Moridani, Majid Y ^a,b  

^a University of Waterloo Health Sciences Campus   (Canada)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Acetylsalicylic acid; Aspirin; B16 F0; B16 F10; C32; Cancer; GSH; Melanoma; MeWo; Quinone; Reactive oxygen species; SK MEL 28; SK MEL 5

Indexed keywords

1 BROMOHEPTANE; ACETYLSALICYLIC ACID; ASCORBIC ACID; CYCLOSPORIN; DICOUMAROL; GLUTATHIONE; HEPTANE DERIVATIVE; MONOPHENOL MONOOXYGENASE; OXYGEN; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SALICYLIC ACID; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; ENZYME METABOLISM; HUMAN; HUMAN CELL; IC 50; MALE; MELANOMA CELL; MICROSCOPY; MITOCHONDRIAL TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; GLUTATHIONE; HUMANS; MELANOCYTES; MELANOMA; MICROSOMES, LIVER; MONOPHENOL MONOOXYGENASE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SKIN NEOPLASMS;

EID: 56849118555     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283107df7     Document Type: Article

References (58)

1. Kern DH, Shoemaker RH, Hildebrand-Zanki SU, Driscoll JS. Structure-activity relationships defining the cytotoxicity of catechol analogues against human malignant melanoma. Cancer Res 1988; 48:5178-5182.
2. Smit NP, Peters K, Menko W, Westerhof W, Pavel S, Riley PA. Cytotoxicity of a selected series of substituted phenols towards cultured melanoma cells. Melanoma Res 1992; 2:295-304.
3. Ordan O, Rotem R, Jaspers I, Flescher E. Stress-responsive JNK mitogen-activated protein kinase mediates ASA-induced suppression of B16 melanoma cellular proliferation. Br J Pharmacol 2003; 138:1156-1162.
4. Naish-Byfield S, Cooksey CJ, Latter AM, Johnson CI, Riley PA. In vitro assessment of the structure-activity relationship of tyrosinase-dependent cytotoxicity of a series of substituted phenols. Melanoma Res 1991; 1:273-287.
5. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. ASA, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13:559-583.
6. Harris RE, Beebe-Donk J, Namboodiri KK. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 2001; 8:655-657.
7. Kast RE. Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. Med Oncol 2007; 24:1-6.
8. Chiu LC, Tong KF, Ooi VE. Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed Pharmacother 2005; 59 (Suppl 2):S293-S297.
9. Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM, Ramsden CA. Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur J Cancer 1997; 33:135-143.
10. Vad NM, Shaik IH, Mehvar R, Moridani MY. Metabolic bioactivation and toxicity of ethyl 4-hydroxy benzoate in human SK-MEL-28 melanoma cells. J Pharm Sci 2007; 97:1934-1945.
11. Moridani MY. Biochemical basis of 4-hydroxyanisole induced cell toxicity towards B16-F0 melanoma cells. Cancer Lett 2006; 243:235-245.
12. Moridani MY, Moore M, Bartsch RA, Yang Y, Heibati-Sadati S. Structural toxicity relationship of 4-alkoxyphenols' cytotoxicity towards murine B16-F0 melanoma cell line. J Pharm Pharm Sci 2005; 8:348-360.
13. Mitropapas G, Nezos A, Halapas A, Pissimissis N, Lembessis P, Sourla A, et al. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. Clin Chem Lab Med 2006; 44:1403-1409.
14. Souza AV, Visconti MA, Castrucci AM. Melatonin biological activity and binding sites in human melanoma cells. J Pineal Res 2003; 34:242-248.
15. Gili A, Thomas PD, Ota M, Jimbow K. Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity. Melanoma Res 2000; 10:9-15.
16. Liu SH, Pan IH, Chu IM. Inhibitory effect of p-hydroxybenzyl alcohol on tyrosinase activity and melanogenesis. Biol Pharm Bull 2007; 30:1135-1139.
17. Jimbow K, Luo D, Chen H, Hara H, Lee MH. Coordinated mRNA and protein expression of human LAMP-1 in induction of melanogenesis after UV-B exposure and co-transfection of human tyrosinase and TRP-1 cDNAs. Pigment Cell Res 1994; 7:311-319.
18. Hara H, Lee MH, Chen H, Luo D, Jimbow K. Role of gene expression and protein synthesis of tyrosinase, TRP-1, lamp-1, and CD63 in UVB-induced melanogenesis in human melanomas. J Invest Dermatol 1994; 102:495-500.
19. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70-77.
20. Moridani MY, Cheon SS, Khan S, O'Brien PJ. Metabolic activation of 4-hydroxyanisole by isolated rat hepatocytes. Drug Metab Dispos 2002; 30:1063-1069.
21. Gergel' D, Cederbaum AI. Interaction of nitric oxide with 2-thio-5-nitrobenzoic acid: implications for the determination of free sulfhydryl groups by ellman's reagent. Arch Biochem Biophys 1997; 347:282-288.
22. Krikun G, Cederbaum AI. Increased microsomal oxidation of alcohols after pyrazole treatment and its similarities to the induction by ethanol consumption. Biochim Biophys Acta 1984; 801:131-137.
23. Dallner G. Isolation of microsomal subfractions by use of density gradients. Methods Enzymol 1978; 52:71-82.
24. Kruger NJ. The Bradford method for protein quantitation. Methods Mol Biol 1994; 32:9-15.
25. Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, et al. Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 2004; 164:2039-2054.
26. Moridani MY, Cheon SS, Khan S, O'Brien PJ. Metabolic activation of 3-hydroxyanisole by isolated rat hepatocytes. Chem Biol Interact 2003; 142:317-333.
27. Shaik IH, Mehvar R. Rapid determination of reduced and oxidized glutathione levels using a new thiol-masking reagent and the enzymatic recycling method: application to the rat liver and bile samples. Anal Bioanal Chem 2006; 385:105-113.
28. Siraki AG, Chan TS, O'Brien PJ. Application of quantitative structure-toxicity relationships for the comparison of the cytotoxicity of 14 p-benzoquinone congeners in primary cultured rat hepatocytes versus PC12 cells. Toxicol Sci 2004; 81:148-159.
29. Preusch PC, Siegel D, Gibson NW, Ross D. A note on the inhibition of DT-diaphorase by dicoumarol. Free Radic Biol Med 1991; 11:77-80.
30. Khan S, O'Brien PJ. 1-bromoalkanes as new potent nontoxic glutathione depletors in isolated rat hepatocytes. Biochem Biophys Res Commun 1991; 179:436-441.
31. Broekemeier KM, Pfeiffer DR. Cyclosporin A-sensitive and insensitive mechanisms produce the permeability transition in mitochondria. Biochem Biophys Res Commun 1989; 163:561-566.
32. Fingrut O, Flescher E. Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia 2002; 16:608-616.
33. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002; 13:535-542.
34. Higuchi S, Tanaka N, Shioiri Y, Otomo S, Aihara H. Two modes of analgesic action of ASA, and the site of analgesic action of salicylic acid. Int J Tissue React 1986; 8:327-331.
35. Denkert C, Köbel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001; 61:303-308.
36. Vogt T, Mcclelland M, Jung B, Popova S, Bogenreider T, Becker B, et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 2001; 11:587-599.
37. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of non steroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999; 190:451-459.
38. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by Aspirin®. Proc Natl Acad Sci U S A 2001; 98:14583-14588.
39. Horani MH, Gobal F, Haas MJ, Wong NC, Mooradian AD. Cyclooxygenase inhibition is associated with downregulation of apolipoprotein AI promoter activity in cultured hepatoma cell line HepG2. Metabolism 2004; 53:174-181.
40. Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615:261-298.
41. Boyle GM, Martyn AC, Parsons PG. Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res 2005; 18:160-166.
42. Kim SH, Ahn S, Han JW, Lee HY, Lee YW, Kim MR, et al. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 2004; 315:964-970.
43. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG. Anti-tumor activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999; 80:1252-1258.
44. Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, Medrano EE. Downregulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002; 62:6231-6239.
45. Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D, Hauschild A. Molecularly targeted therapy for melanoma. Cancer 2006; 107:2317-2327.
46. Simonova M, Wall A, Weissleder R, Bogdanov A Jr. Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. Cancer Res 2000; 60:6656-6662.
47. Roberts LJ, Morrow JD. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Goodman Gilman A, editor. The pharmacological basis of therapeutics. 10th ed. USA: McGraw-Hill; 2001. pp. 687-731.
48. Benedito MA. Gender differences in the activities of ASA-esterases in rat tissues. Braz J Med Biol Res 1998; 31:1113-1118.
49. Meister A. Glutathione, ascorbate, and cellular protection. Cancer Res 1994; 54(Suppl):S1969-S1975.
50. Benathan M, Alvero-Jackson H, Mooy AM. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells. Melanoma Res 1992; 2:304-314.
51. Peinado P, Liarte-Martinez JH, Marmol V, Solano F, Lozano JA. Glutathione depletion in mouse melanoma cells increases their sensitivity to oxidative lysis. Cancer J 1992; 5:348-353.
52. Wolchok JD, Williams L, Pinto JT, Fleisher M, Krown SE, Hwu WJ, et al. Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res 2003; 13:189-196.
53. Mitchell DB, Acosta D, Bruckner JV. Role of glutathione depletion in the cytotoxicity of acetaminophen in a primary culture system of rat hepatocytes. Toxicology 1985; 37:127-146.
54. Viña J, Romero FJ, Estrela JM, Viña JR. Effect of acetaminophen (paracetamol) and its antagonists on glutathione (GSH) content in rat liver. Biochem Pharmacol 1980; 29:1968-1970.
55. Begleiter A. Studies on the mechanism of action of quinone antitumor agents. Biochem Pharm 1985; 34:2629-2636.
56. Adelman R, Saul RL, Ames BN. Oxidative damage to DNA: relation to species metabolic rate and life span. Proc Natl Acad Sci U S A 1988; 85:2706-2708.
57. Wood JM, Schallreuter KU. Studies on the reactions between human tyrosinase, superoxide anion, hydrogen peroxide and thiols. Biochim Biophys. Acta 1991; 1074:378-385.
58. O'Neil MJ, Smith A, Heckelman PE. The Merck Index: an encyclopedia of chemicals, drugs, and biologicals. 13th ed. USA: Merck & Co, INC; 2001.